Drug Trial Radar · NCT07822477
A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIV
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Nov 6, 2026
Primary completion
May 9, 2029
Study completion May 9, 2029
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Sep 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study aims to evaluate the safety, tolerability and pharmacokinetic (PK) properties of a single dose of VH5356136 in adult participants without human immunodeficiency virus (HIV). This study will be conducted following the availability of initial safety and PK clinical data from formulation of the parent drug VH4524184.
Conditions
- HIV Infections
Interventions
VH5356136 Formulation 1Drug
Participants will receive VH5356136 Formulation 1 on Day 1.
VH5356136 Formulation 2Drug
Participants will receive VH5356136 Formulation 2 on Day 1.
Placebo for VH5356136 Formulation 1Drug
Participants will receive placebo for VH5356136 Formulation 1 on Day 1.
Placebo for VH5356136 Formulation 2Drug
Participants will receive placebo for VH5356136 Formulation 2 on Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with drug-related adverse events (AEs)Time frame: From Day 1 to Month 18
- Number of participants with Grade 2 to Grade 5 AEsTime frame: From Day 1 to Month 18
- Number of participants with serious adverse events (SAEs)Time frame: From Day 1 to Month 18
- Area under the concentration time curve from zero (pre-dose) to the last quantifiable concentration (post dose) (AUC[0-tlast]) for VH5356136Time frame: From Day 1 (pre-dose) up to Month 18 post-dose
- AUC(0-tlast) for VH4524184Time frame: From Day 1 (pre-dose) up to Month 18 post-dose
- Maximum plasma concentration (Cmax) for VH5356136Time frame: From Day 1 (pre-dose) up to Month 18 post-dose
- Cmax for VH4524184Time frame: From Day 1 (pre-dose) up to Month 18 post-dose
- Time to maximum observed plasma drug concentration (tmax) for VH5356136Time frame: From Day 1 (pre-dose) up to Month 18 post-dose
- Tmax for VH4524184Time frame: From Day 1 (pre-dose) up to Month 18 post-dose
- Terminal half-life (t1/2) for VH5356136Time frame: From Day 1 (pre-dose) up to Month 18 post-dose
- t1/2 for VH4524184Time frame: From Day 1 (pre-dose) up to Month 18 post-dose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.